Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on March 23, 2023, regarding events occurring on that date. The filing primarily addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the appointment of Catherine Sohn, Pharm.D., to the Board of Directors, effective March 23, 2023. Dr. Sohn brings extensive experience from roles at Jazz Pharmaceuticals, Axcellea Health, Maze Therapeutics, and GlaxoSmithKline.
Guidance, Outlook, and Compensation
There is no guidance, outlook, or management commentary regarding future financial performance in this filing. Regarding the new director appointment:
- Compensation: Dr. Sohn will receive an annual cash retainer of $40,000.
- Equity: She received an initial option award to purchase 47,000 shares of common stock under the 2017 Omnibus Incentive Plan.
- Agreements: An indemnification agreement was entered into, consistent with those for other directors.
Investor Verification Checklist
- Verify the effective date of Dr. Sohn's board appointment (March 23, 2023).
- Confirm the specific terms of the 47,000 share option award granted to Dr. Sohn.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.